Chen et al. 2018
|Population: NMES+carbamazepine group: Mean age=41.8±12.6 yr; Gender: males=25, females=2; Time since injury=31.2±11.5 mo; Level of injury: C=12, T=13, L=2; Severity of injury: AIS A=16, B=3, C=5, D=3; Type of pain=neuropathic.
Carbamazepine group: Mean age=43.5±13.7 yr; Gender: males=23, females=4; Time since injury=29.7±10.8 mo; Level of injury: C=14, T=10, L=3; Severity of injury: AIS A=18, B=2, C=3, D=4; Type of pain=neuropathic.
Intervention: Participants were assigned to either an NMES + carbamazepine group or a carbamazepine only group for 3 mo of treatment with outcomes measures at baseline and post-intervention.
Outcome Measures: Pain intensity numerical rating scale (NRS), quality of life (QOL) sort form 36 (SF-36) scale, and adverse events.
*Neuromuscular electrical stimulation (NMES), neuropathic pain (NPP)
|1. No significant difference in NRS for NPP or the QOL in SF-36 in the NMES group (p>0.05).
2. No serious adverse events in either group.